M
Michael I. Barbato
Researcher at St. Jude Children's Research Hospital
Publications - 6
Citations - 1684
Michael I. Barbato is an academic researcher from St. Jude Children's Research Hospital. The author has contributed to research in topics: EP300 & Leukemia. The author has an hindex of 3, co-authored 3 publications receiving 1500 citations. Previous affiliations of Michael I. Barbato include Memorial Sloan Kettering Cancer Center.
Papers
More filters
Journal ArticleDOI
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia
Jinghui Zhang,Li Ding,Linda Holmfeldt,Gang Wu,Susan L. Heatley,Susan L. Heatley,Debbie Payne-Turner,John Easton,Xiang Chen,Jianmin Wang,Michael Rusch,Charles Lu,Shann Ching Chen,Lei Wei,J. Racquel Collins-Underwood,Jing Ma,Kathryn G. Roberts,Stanley Pounds,Anatoly Ulyanov,Jared Becksfort,Pankaj Gupta,Robert Huether,Richard W. Kriwacki,Matthew Parker,Daniel J. McGoldrick,David Zhao,Daniel Alford,Stephen Espy,Kiran Chand Bobba,Guangchun Song,Deqing Pei,Cheng Cheng,Stefan Roberts,Michael I. Barbato,Michael I. Barbato,Dario Campana,Dario Campana,Elaine Coustan-Smith,Elaine Coustan-Smith,Sheila A. Shurtleff,Susana C. Raimondi,Maria Kleppe,Maria Kleppe,Jan Cools,Kristin A. Shimano,Michelle L. Hermiston,Sergei Doulatov,Kolja Eppert,Elisa Laurenti,Faiyaz Notta,John E. Dick,Giuseppe Basso,Stephen P. Hunger,Mignon L. Loh,Meenakshi Devidas,Brent L. Wood,Stuart S. Winter,Kimberley P. Dunsmore,Robert S. Fulton,Lucinda Fulton,Xin Hong,Chris Harris,David J. Dooling,Kerri Ochoa,Kimberly J. Johnson,John C. Obenauer,William E. Evans,Ching-Hon Pui,Clayton W. Naeve,Timothy J. Ley,Elaine R. Mardis,Richard K. Wilson,James R. Downing,Charles G. Mullighan +73 more
TL;DR: The mutational spectrum is similar to myeloid tumours, and moreover, the global transcriptional profile of ETP ALL was similar to that of normal andMyeloid leukaemia haematopoietic stem cells, suggesting that addition of myeloids-directed therapies might improve the poor outcome of E TP ALL.
Journal ArticleDOI
An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia.
Tanja A. Gruber,Amanda Larson Gedman,Jinghui Zhang,Cary Koss,Suresh Marada,Huy Q. Ta,Shann Ching Chen,Xiaoping Su,Stacey K. Ogden,Jinjun Dang,Gang Wu,Vedant Gupta,Anna Andersson,Stanley Pounds,Lei Shi,John Easton,Michael I. Barbato,Heather L. Mulder,Jayanthi Manne,Jianmin Wang,Michael Rusch,Swati Ranade,Ramapriya Ganti,Matthew Parker,Jing Ma,Ina Radtke,Li Ding,Li Ding,Giovanni Cazzaniga,Andrea Biondi,Steven M. Kornblau,Farhad Ravandi,Hagop M. Kantarjian,Stephen D. Nimer,Konstanze Döhner,Hartmut Döhner,Timothy J. Ley,Timothy J. Ley,Paola Ballerini,Sheila A. Shurtleff,Daisuke Tomizawa,Souichi Adachi,Yasuhide Hayashi,Akio Tawa,Lee Yung Shih,Der Cherng Liang,Jeffrey E. Rubnitz,Ching-Hon Pui,Elaine R. Mardis,Elaine R. Mardis,Richard K. Wilson,Richard K. Wilson,James R. Downing +52 more
TL;DR: In this article, the authors performed transcriptome sequencing on diagnostic blasts from 14 pediatric patients and validated their findings in a recurrency/validation cohort consisting of 34 pediatric and 28 adult AMKL samples.
Journal ArticleDOI
Discovery of Novel Recurrent Mutations in Childhood Early T-Cell Precursor Acute Lymphoblastic Leukemia by Whole Genome Sequencing - a Report From the St Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project
Jinghui Zhang,Li Ding,Linda Holmfeldt,Gang Wu,Susan L. Heatley,Debbie Payne-Turner,John Easton,Xiang Chen,Jianmin Wang,Michael Rusch,Charles Lu,Shann-Ching Chen,Racquel Collins-Underwood,Jing Ma,Kathryn G. Roberts,Stanley Pounds,Lei Wei,Anatoly Ulyanov,Jared Becksfort,Pankaj Gupta,Robert Huether,Richard W. Kriwacki,Daniel J. McGoldrick,David Zhao,Daniel Alford,Stephen Espy,Kiran Chand Bobba,Guangchun Song,Deqing Pei,Cheng Cheng,Stefan Roberts,Michael I. Barbato,Dario Campana,Elaine Coustan-Smith,William E. Evans,Sheila A. Shurtleff,Maria Kleppe,Jan Cools,Kristin A. Shimano,Michelle L. Hermiston,Sergei Doulatov,Kolja Eppert,Elisa Laurenti,Faiyaz Notta,John E. Dick,Giuseppe Basso,Stephen P. Hunger,Mignon L. Loh,Meenakshi Devidas,Brent L. Wood,Stuart S. Winter,Kimberly P. Dunsmore,Robert S. Fulton,Lucinda Fulton,Xin Hong,Chris Harris,David J. Dooling,Kerri Ochoa,Kimberly J. Johnson,John C. Obenauer,Ching-Hon Pui,Susana C. Raimondi,Clayton W. Naeve,Timothy J. Ley,Elaine R. Mardis,Richard K. Wilson,James R. Downing,Charles G. Mullighan +67 more
TL;DR: Results of whole genome sequencing of tumor and normal DNA from 12 children with ETP ALL show a high frequency of activating mutations in genes regulating cytokine receptor and Ras signalling are identified, including GATA3 regulates early T cell development, and mutations in this gene were observed exclusively in ETP All.
Journal ArticleDOI
A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-associated Renal Cell Carcinoma.
John A. Ligon,Russell Sundby,M. F. Wedekind Malone,Fernanda I. Arnaldez,Jaydira Del Rivero,Lori Wiener,Ramaprasad Srinivasan,Melissa Spencer,Amanda Carbonell,Haiyan Lei,Jack F. Shern,Seth M. Steinberg,William D. Figg,Cody J. Peer,S. Zimmerman,Josquin Moraly,Xia Xu,S Fox,K Chan,Michael I. Barbato,Thorkell Andresson,Naomi Taylor,Karel Pacak,J. Keith Killian,Eva Dombi,W. Marston Linehan,Markku Miettinen,Richard Piekarz,Lee J. Helman,Paul S. Meltzer,Brigitte C. Widemann,John Glod +31 more
TL;DR: Guadecitabine did not meet the target of 30% response rate across dSDH tumors at this dose, though signs of biologic activity were noted.
Journal ArticleDOI
Donor T cell DNMT3a regulates alloreactivity in mouse models of hematopoietic stem cell transplantation
Yiouli P. Ktena,Michael A. Koldobskiy,Michael I. Barbato,Han-Hsuan Fu,Leo Luznik,Nicolas J. Llosa,Azeb Haile,Orly R. Klein,Chen Liu,Christopher Gamper,Kenneth R. Cooke +10 more
TL;DR: A critical role for DNMT3a is demonstrated in regulating T cell alloreactivity and pathways that control T cell tolerance are revealed, which provide a platform for deciphering clinical data that associate donor DN MT3a mutations with increased GVHD, decreased relapse, and improved survival.